



Ref: A.19 Methylphenidate – attention deficit hyperactivity disorder

Dear Members of the EML Secretariat and the WHO Expert Committee on Selection and Use of Essential Medicines,

The Romanian Society of Child and Adolescent Neurology and Psychiatry (RSCANP), through its President, wishes to express its support for the inclusion of methylphenidate in the World Health Organization's Essential Medicines List for the treatment of attention deficit hyperactivity disorder (ADHD).

We believe that the inclusion of this medication on the WHO list is essential to facilitate equitable access for children and adolescents diagnosed with ADHD to safe, effective, and standardized treatments.

ADHD is a neurodevelopmental disorder with a significant impact on quality of life, education, and social integration, and pharmacological treatment, in combination with psychotherapeutic and educational interventions, it is effective in reducing symptoms and improving overall functioning.

Methylphenidate is approved and used in Romania, where it is part of the ADHD treatment protocol, with favorable outcomes in clinical practice. In Romania, methylphenidate is classified as a high-risk drug according to Article 1 of Law 143/2000 on preventing and combating illicit drug trafficking and use, and it is authorized under the trade name Concerta 18 mg, 36 mg, 54 mg.

In this context, we support the recommendation for the inclusion of methylphenidate in the WHO Essential Medicines List and advocate for the importance of its availability at a global level.

We thank you for the opportunity to contribute to this important endeavor and express our readiness to collaborate in future initiatives dedicated to improving access to services and treatments for the mental health of children and adolescents.

With highest consideration,

Assistant Professor Dr. Adriana Cojocaru

President of the Romanian Society of Child and Adolescent Neurology and Psychiatry (RSCANP)